Reply to G. Keramida et al
J Clin Oncol
.
2015 Dec 1;33(34):4121-2.
doi: 10.1200/JCO.2015.63.2125.
Epub 2015 Aug 24.
Authors
Sally F Barrington
1
,
N George Mikhaeel
2
,
Lale Kostakoglu
3
,
Michel Meignan
4
,
Martin Hutchings
5
,
Stefan Müeller
6
,
Lawrence H Schwartz
7
,
Emanuele Zucca
8
,
Richard I Fisher
9
,
Judith Trotman
10
,
Otto S Hoekstra
11
,
Rodney J Hicks
12
,
Michael J O'Doherty
13
,
Roland Hustinx
14
,
Alberto Biggi
15
,
Bruce D Cheson
16
Affiliations
1
King's College London, London, United Kingdom
[email protected]
.
2
Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom.
3
Mount Sinai Medical Center, New York, NY.
4
Centre Universitaire Hospitalier Henri Mondor, Paris, France.
5
Copenhagen University Hospital, Copenhagen, Denmark.
6
Universitätsklinikum Essen, Essen, Germany.
7
Columbia University Medical Center, New York, NY.
8
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
9
Fox Chase Cancer Center, Philadelphia, PA.
10
Concort Hospital and University of Sydney, Sydney, New South Wales, Australia.
11
Vrije Universiteit Medical Centre, Amsterdam, the Netherlands.
12
Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.
13
King's College London, London, United Kingdom.
14
University of Liège, Liège, Belgium.
15
Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.
16
Georgetown University Hospital, Washington, DC.
PMID:
26304890
DOI:
10.1200/JCO.2015.63.2125
No abstract available
Publication types
Letter
Comment
MeSH terms
Fluorodeoxyglucose F18*
Humans
Lymphoma / diagnostic imaging*
Lymphoma / therapy*
Positron-Emission Tomography*
Radiopharmaceuticals*
Tomography, X-Ray Computed*
Substances
Radiopharmaceuticals
Fluorodeoxyglucose F18